Pediatrics - Acne

Pediatrics - Acne

Basics

Description

Acne vulgaris is one of the most common dermatological conditions affecting children and adolescents. It is a chronic inflammatory disorder involving the pilosebaceous units, which consist of hair follicles and their associated sebaceous glands.

Pilosebaceous units are particularly concentrated on the face, chest, back, shoulders, and upper arms. Consequently, these areas are the most frequently affected by acne.

Acne may present with noninflammatory lesions, such as open and closed comedones, or inflammatory lesions, including papules, pustules, nodules, and deep inflammatory lesions.

Persistent or severe inflammation may lead to permanent atrophic scarring, postinflammatory hyperpigmentation, and considerable psychosocial distress.

The clinical presentation, associated systemic abnormalities, and appropriate treatment vary according to the patient’s age, pubertal development, and disease severity.

Classification Of Acne According To Age

Neonatal Acne

Neonatal acne generally develops between birth and six weeks of age and affects approximately 20% of newborns.

It typically presents as small inflammatory papules and pustules, predominantly affecting the cheeks, forehead, and other facial areas.

Many cases previously described as neonatal acne are now recognized as neonatal cephalic pustulosis, a closely related but distinct eruption characterized by the absence of comedones.

Colonization by Malassezia species has been proposed as a contributing factor in neonatal cephalic pustulosis, although the precise causal relationship remains uncertain.

The condition is usually benign and self-limiting, and most affected newborns do not require treatment.

When lesions are severe or persistent, topical antifungal treatment, such as ketoconazole 2% cream, may be considered after appropriate clinical assessment.

Infantile Acne

Infantile acne develops between approximately six weeks and one year of age.

Unlike neonatal cephalic pustulosis, infantile acne may present with true comedones and inflammatory lesions, including papules, pustules, and occasionally nodules.

The lesions predominantly involve the face, especially the cheeks.

Most affected infants do not have an underlying endocrine disorder.

Infantile acne commonly resolves spontaneously, although severe or persistent disease may require topical acne treatment to reduce inflammation and prevent scarring.

Some evidence suggests that children with a history of significant infantile acne may have an increased likelihood of developing more severe acne during adolescence.

Midchildhood Acne

Midchildhood acne occurs between approximately one and six years of age and is relatively uncommon.

It generally presents with comedonal and inflammatory lesions involving the face.

Because circulating androgen levels are normally low during much of this developmental period, acne appearing at this age raises concern for an underlying endocrine abnormality.

Potential causes include premature androgen production, congenital adrenal hyperplasia, and androgen-secreting tumors.

Children with midchildhood acne should undergo careful assessment for evidence of androgen excess, with pediatric endocrinology referral when indicated.

Preadolescent Acne

Preadolescent acne generally appears between approximately seven and eleven years of age, although age boundaries vary slightly across classification systems.

It most frequently presents with comedonal lesions involving the central face, particularly the forehead, nose, and chin.

This distribution is commonly referred to as the T-zone.

Preadolescent acne may represent one of the earliest clinical manifestations of pubertal development, reflecting increasing androgen activity.

In the absence of other signs suggesting abnormal hormonal development, extensive endocrine investigation is usually unnecessary.

Adolescent Acne

Adolescent acne typically occurs between twelve and nineteen years of age.

It is extremely common, affecting approximately 85% of adolescents.

The disease may involve comedonal, inflammatory, nodular, or mixed lesions.

Facial involvement is frequent, although the chest, back, and shoulders may also be affected.

Disease severity ranges from mild comedonal acne to extensive inflammatory acne associated with permanent scarring.

Adolescent acne may significantly affect self-esteem, social interactions, emotional well-being, and quality of life.

Risk Factors

Genetics

Genetic factors contribute significantly to susceptibility to acne vulgaris.

Familial clustering is common, and individuals with affected parents or siblings may have an increased likelihood of developing acne.

Although inherited susceptibility is well recognized, acne does not follow a single consistent Mendelian inheritance pattern.

Instead, it is considered a multifactorial condition influenced by several genetic and environmental factors.

General Prevention

Early recognition and effective treatment of acne can reduce the risk of permanent scarring, persistent postinflammatory pigmentation, and psychosocial complications.

The principal preventive approach involves appropriate skin care, avoidance of aggravating factors, and timely treatment of active inflammatory lesions.

Skin Care

Patients should use gentle cleansing products that do not excessively irritate or dry the skin.

Oil-free, noncomedogenic moisturizers may help maintain the skin barrier and improve tolerance of acne medications.

Sun Protection

Regular application of noncomedogenic sunscreen is recommended, particularly in patients using medications that may increase skin irritation or sun sensitivity.

Broad-spectrum sunscreen with a sun protection factor of at least 30 is generally appropriate.

Cosmetics And Personal Care Products

Oil-free and noncomedogenic makeup, sunscreens, moisturizers, and hair products are preferred.

Heavy or occlusive products may contribute to follicular blockage and aggravate acne in susceptible individuals.

Prevention Of Scarring

Inflammatory lesions should be treated promptly, particularly when nodules, deep inflammatory lesions, or early scars are present.

Patients should avoid squeezing, picking, or manipulating acne lesions because these behaviors may increase inflammation, pigmentary changes, and scarring.

Pathophysiology

Acne vulgaris develops through the interaction of several processes involving the pilosebaceous unit.

Four major pathophysiological mechanisms contribute to the formation and progression of acne lesions.

Increased Sebum Production

Sebaceous gland activity is stimulated by androgens, resulting in increased production of sebum.

Androgen activity is relatively prominent during early infancy because of transient physiological hormonal activity.

It subsequently decreases during childhood before increasing again during adrenarche and puberty.

Sebum production becomes particularly prominent during adolescence and generally declines during early adulthood, although acne may persist beyond the teenage years.

Excessive sebum creates an environment that favors follicular obstruction and microbial activity.

Abnormal Follicular Keratinization

Altered growth and differentiation of keratinocytes within the follicular epithelium cause excessive accumulation of keratinized cells.

These cells combine with sebum and obstruct the follicular opening, producing a microscopic lesion known as a microcomedone.

Microcomedones are the precursors of both inflammatory and noninflammatory acne lesions.

As follicular obstruction progresses, open or closed comedones may develop.

Cutibacterium Acnes Colonization

Cutibacterium acnes, formerly known as Propionibacterium acnes, is an anaerobic, gram-positive bacterium commonly present within pilosebaceous follicles.

This organism can contribute to acne inflammation through interactions with sebum, follicular cells, and the immune system.

Its metabolic activity includes the breakdown of sebum triglycerides into free fatty acids, which may promote local irritation and inflammatory responses.

The contribution of C. acnes to acne depends not simply on bacterial abundance but also on microbial strain characteristics, follicular conditions, and host immune responses.

Inflammation And Immune Activation

Acne involves activation of both innate and adaptive immune pathways.

Inflammatory mediators are released in response to follicular abnormalities, microbial factors, and tissue injury.

These processes contribute to the development of inflammatory papules, pustules, nodules, and deeper lesions.

Severe or prolonged inflammation can damage surrounding dermal tissue, increasing the likelihood of permanent scarring.

Etiology

Acne has a multifactorial etiology involving hormonal influences, genetic susceptibility, follicular obstruction, microbial factors, and inflammation.

Several additional factors may precipitate or aggravate the disorder.

Androgen Excess

Increased androgen activity stimulates sebaceous gland growth and sebum production.

Androgen-related acne may occur as part of normal pubertal development or result from pathological androgen excess.

When acne develops unusually early, is particularly severe, or is accompanied by signs of virilization, an underlying endocrine disorder should be considered.

Medication-Induced Acne

Certain medications may induce acneiform eruptions or worsen preexisting acne.

Potential contributing medications include systemic or topical corticosteroids, selected anticonvulsants, lithium, and some hormonal preparations.

Medication-associated acne may differ from typical acne vulgaris because lesions are sometimes more uniform in appearance and may lack comedones.

Follicular Occlusion

Occlusive cosmetic products, oil-based skin preparations, and heavy topical substances may obstruct follicular openings.

These products can worsen comedonal acne, particularly in individuals with naturally oily skin.

Mechanical Friction

Repeated friction, pressure, heat, and occlusion may aggravate acne in areas exposed to tight clothing or athletic equipment.

Examples include helmets, chin straps, shoulder pads, sports equipment, and bra straps.

This presentation is sometimes described as acne mechanica.

Commonly Associated Conditions

Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is an endocrine disorder associated with hyperandrogenism and ovulatory dysfunction.

Acne may occur alongside irregular menstrual cycles, hirsutism, androgenic alopecia, and metabolic abnormalities.

The diagnosis of PCOS in adolescents requires careful interpretation of pubertal development because menstrual irregularity and acne can occur physiologically during adolescence.

SAPHO Syndrome

SAPHO syndrome is an uncommon inflammatory disorder characterized by a combination of:

• Synovitis.
• Acne.
• Pustulosis.
• Hyperostosis.
• Osteitis.

Severe acne may occasionally occur as part of this multisystem inflammatory condition.

Adrenal Or Gonadal Tumors

Androgen-producing adrenal, ovarian, or testicular tumors may cause rapid-onset or unusually severe acne.

Associated manifestations may include accelerated growth, virilization, hirsutism, or other signs of increased androgen activity.

Nonclassic Congenital Adrenal Hyperplasia

Nonclassic congenital adrenal hyperplasia, frequently associated with partial 21-hydroxylase deficiency, may cause excessive adrenal androgen production.

Clinical manifestations may include acne, premature pubarche, hirsutism, and menstrual irregularities.

Diagnosis

The diagnosis of acne vulgaris is primarily clinical and is based on the appearance, distribution, and types of skin lesions.

Assessment should determine disease severity, identify contributing factors, evaluate the risk of scarring, and recognize signs suggesting an underlying systemic disorder.

History

Age Of Onset

The age at which acne first appears is an important diagnostic consideration.

Acne beginning during adolescence is generally consistent with physiological pubertal androgen activity.

Acne developing during midchildhood, or unusually severe acne appearing before expected puberty, may suggest pathological androgen excess.

Sudden onset of severe acne associated with virilization or rapid progression also warrants endocrine evaluation.

Medication And Supplement Use

A detailed medication history should identify drugs and supplements that may contribute to acne.

Potential aggravating agents include:

• Androgenic hormonal preparations.
• Some combined oral contraceptive formulations.
• Progestin implants.
• Depot medroxyprogesterone acetate.
• Topical, inhaled, or systemic corticosteroids.
• Selected anticonvulsants.
• Lithium.
• Isoniazid.
• Nicotine-containing products.
• Certain bodybuilding or androgen-containing supplements.

The relationship between medication initiation and acne development should be assessed.

Menstrual History

In postmenarchal adolescents, menstrual history may provide clues regarding hormonal influences on acne.

Some patients experience increased acne activity before menstruation because of cyclic hormonal changes.

Irregular menstrual cycles, particularly when accompanied by hirsutism or other manifestations of hyperandrogenism, may suggest an underlying endocrine disorder.

Signs Of Androgen Excess In Prepubertal Children

Clinical features that may suggest abnormal androgen exposure or production include:

• Acne developing unusually early.
• Premature adult-type body odor.
• Accelerated linear growth.
• Early appearance of axillary hair.
• Premature pubic hair development.
• Early genital maturation.
• Clitoromegaly or other signs of virilization.

The presence of these findings warrants further assessment for endocrine abnormalities.

Signs Of Androgen Excess After Puberty

In adolescents, hyperandrogenism may present with:

• Androgenic alopecia.
• Excessive facial or body hair growth.
• Central or truncal obesity.
• Acanthosis nigricans.
• Irregular menstrual cycles.
• Increased muscle mass.
• Other virilizing features.

These manifestations should prompt consideration of endocrine conditions such as PCOS, congenital adrenal hyperplasia, or androgen-producing tumors.

Previous Acne Treatment

The clinician should review all previously attempted acne treatments.

Important information includes the specific medications used, treatment duration, response, adverse effects, and reasons for discontinuation.

Common factors contributing to treatment failure include poor adherence, medication cost, excessive irritation, inconvenient treatment schedules, and unrealistic expectations regarding the speed of improvement.

Psychological Impact

The emotional and social consequences of acne should be assessed in all patients, particularly adolescents with moderate to severe disease.

Questions should address self-esteem, embarrassment, avoidance of social situations, school attendance, depressive symptoms, and the impact of acne on daily life.

Assessment for suicidal ideation is important when depressive symptoms or other significant psychological concerns are identified.

Physical Examination

Skin Examination

The skin examination should assess lesion distribution, morphology, number, inflammatory severity, and evidence of scarring or pigmentary changes.

Commonly affected areas include the face, chest, back, shoulders, and upper arms.

Comedonal Lesions

Open Comedones: Commonly known as blackheads, these lesions consist of dilated follicular openings containing keratin and sebum.

Their dark color results primarily from oxidation and pigmentation of follicular contents rather than accumulated dirt.

Closed Comedones: Also called whiteheads, these lesions appear as small, skin-colored or whitish papules resulting from follicular obstruction beneath a relatively closed surface.

Inflammatory Lesions

Papules: Small, elevated, erythematous inflammatory lesions without visible purulent contents.

Pustules: Inflamed lesions containing visible purulent material.

Nodules: Larger, deeper inflammatory lesions that may be painful and are associated with an increased risk of scarring.

Deep Inflammatory Or Pseudocystic Lesions: Severe inflammatory lesions that may resemble cysts clinically but do not necessarily represent true epithelial-lined cysts.

Scarring And Pigmentary Changes

The examination should identify atrophic scars, raised scars, and areas of postinflammatory hyperpigmentation or erythema.

The presence of scarring indicates a need for effective treatment to prevent additional permanent skin damage.

Assessment Of Acne Severity

Global severity should be determined by considering:

• Number of lesions.
• Type and size of lesions.
• Distribution and extent of involvement.
• Degree of inflammation.
• Presence of nodules.
• Existing scarring.
• Associated pigmentary changes.
• Psychosocial impact.

Examination For Androgen Excess

Patients should be examined for hirsutism, androgenic alopecia, acanthosis nigricans, abnormal pubertal development, and other signs of hyperandrogenism.

Growth And Vital Signs

Height, weight, growth velocity, and pubertal development should be assessed when an endocrine disorder is suspected.

Blood pressure measurement may be appropriate as part of the general assessment, particularly when systemic disease is a concern.

Differential Diagnosis

Several dermatological conditions may resemble acne vulgaris, especially when inflammatory papules or pustules are present without comedones.

Facial Angiofibromas

Facial angiofibromas, historically called adenoma sebaceum, are small vascular and fibrous papules that may occur in patients with tuberous sclerosis complex.

They commonly involve the central face and may resemble inflammatory acne lesions.

Keratosis Pilaris

Keratosis pilaris is characterized by small, rough, follicular papules caused by keratin accumulation.

It commonly affects the cheeks, upper arms, and thighs.

Flat Warts

Flat warts are caused by human papillomavirus infection and present as small, smooth, flat-topped papules.

They may involve the face and resemble noninflammatory acne lesions.

Molluscum Contagiosum

Molluscum contagiosum is a viral skin infection characterized by dome-shaped, often centrally umbilicated papules.

The lesions may occasionally resemble acneiform papules.

Periorificial Dermatitis

Periorificial dermatitis presents with small inflammatory papules or pustules concentrated around the mouth, nose, or eyes.

It may be associated with topical corticosteroid exposure.

Milia

Milia are small, superficial, keratin-filled cysts that appear as firm, white or yellowish papules.

They commonly occur on the face and may resemble closed comedones.

Miliaria

Miliaria develops when sweat ducts become obstructed.

It produces small papules or vesicles, particularly in warm or humid environments.

Syringomas

Syringomas are benign sweat duct tumors that typically appear as small, firm, skin-colored papules around the eyelids.

Demodex Folliculitis

Demodex-associated folliculitis may produce inflammatory follicular papules and pustules.

It may resemble acne, although comedones are usually absent.

Malassezia Folliculitis

Malassezia folliculitis, previously called Pityrosporum folliculitis, presents with relatively uniform, often itchy follicular papules and pustules.

The lesions commonly involve the upper trunk, shoulders, and forehead.

Gram-Negative Folliculitis

Gram-negative folliculitis may develop in patients receiving prolonged antibiotic treatment for acne.

It can present with a sudden increase in inflammatory pustules, often involving the perinasal or perioral region.

Staphylococcal Folliculitis

Staphylococcal folliculitis is a bacterial infection of hair follicles that produces erythematous papules and pustules.

Unlike acne vulgaris, comedones are generally absent.

Chloracne

Chloracne is an acneiform disorder associated with exposure to certain chlorinated aromatic hydrocarbons.

It may produce prominent comedones and cyst-like lesions in characteristic distributions.

Papular Sarcoidosis

Cutaneous sarcoidosis may occasionally produce papular lesions that resemble acne.

Other systemic or cutaneous manifestations may help distinguish it from acne vulgaris.

Diagnostic Tests And Interpretation

Laboratory investigations are not routinely required for uncomplicated acne vulgaris in otherwise healthy children and adolescents.

Further testing should be considered when acne develops at an unusual age, is particularly severe or resistant to appropriate treatment, or is accompanied by clinical evidence of androgen excess.

Indications For Endocrine Evaluation

Endocrine investigations may be appropriate in patients with:

• Acne developing during midchildhood.
• Unusually early or late onset of significant acne.
• Rapidly progressive or severe acne with signs of virilization.
• Premature pubic or axillary hair development.
• Accelerated linear growth.
• Menstrual irregularities associated with hyperandrogenism.
• Hirsutism, androgenic alopecia, or other evidence of excessive androgen activity.
• Acne that remains difficult to control despite appropriate conventional therapy when an endocrine disorder is suspected.

Hormonal Investigations

When clinically indicated, laboratory evaluation may include:

Luteinizing Hormone: Luteinizing hormone (LH) may provide information about hypothalamic-pituitary-gonadal axis activity.

Follicle-Stimulating Hormone: Follicle-stimulating hormone (FSH) may be measured as part of an endocrine assessment.

Total And Free Testosterone: Elevated concentrations may indicate increased androgen production.

Dehydroepiandrosterone Sulfate: DHEA-S is useful for assessing adrenal androgen activity.

Androstenedione: Increased androstenedione may occur in certain adrenal or gonadal disorders.

Prolactin: Prolactin measurement may be appropriate in selected patients with menstrual abnormalities or other findings suggesting endocrine dysfunction.

17-Hydroxyprogesterone: Measurement may help screen for congenital adrenal hyperplasia, particularly nonclassic 21-hydroxylase deficiency.

Hormonal test results should be interpreted according to age, sex, pubertal development, and the timing of specimen collection.

Bone Age Assessment

A bone age radiograph may be useful when premature androgen activity or abnormal pubertal development is suspected.

Advanced skeletal maturation may support the presence of excessive androgen exposure.

Pediatric Endocrinology Referral

Referral to a pediatric endocrinologist is appropriate when clinical findings or laboratory results suggest an underlying hormonal disorder.

Imaging Studies

Imaging of the adrenal glands or gonads may be indicated when clinical and biochemical findings raise concern for an androgen-secreting tumor.

Imaging should be directed by the suspected endocrine abnormality rather than performed routinely for acne.

Laboratory Monitoring During Isotretinoin Therapy

Patients receiving oral isotretinoin require appropriate laboratory assessment because treatment may affect hepatic enzymes and serum lipid concentrations.

Baseline Investigations

Before initiating isotretinoin, laboratory investigations generally include:

• Serum triglycerides and cholesterol.
• Liver transaminases, particularly ALT and AST.
• Pregnancy testing in patients who can become pregnant, according to applicable regulatory requirements.

Routine baseline complete blood count testing is not generally necessary in otherwise healthy patients unless another clinical indication exists.

Monitoring During Treatment

Liver enzymes and lipid levels should be reassessed according to the patient’s risk factors, isotretinoin dose, and clinical course.

Current acne guidelines do not require routine monthly complete blood counts in healthy individuals receiving isotretinoin.

The frequency of lipid and liver enzyme testing may also be individualized rather than automatically repeated every month in every patient.

Pregnancy testing must follow the applicable risk-management requirements for patients who can become pregnant.

Pregnancy Prevention Requirements

Isotretinoin is highly teratogenic and must not be used during pregnancy.

Patients who can become pregnant require appropriate pregnancy screening, counseling, and reliable pregnancy prevention.

In the United States, isotretinoin is regulated through the iPLEDGE risk-management program.

Requirements include pregnancy testing before treatment and continued monitoring during treatment, with specific procedures determined by the current program rules.

The FDA-approved iPLEDGE changes scheduled for implementation on November 15, 2026, include revised procedures for pregnancy testing during and after treatment. Until then, existing requirements and FDA enforcement policies remain applicable.

Treatment

General Principles

Treatment should be individualized according to the patient’s age, acne severity, previous treatment response, skin sensitivity, and risk of permanent scarring.

The choice of treatment should also consider medication affordability, formulation preference, complexity of the treatment regimen, and psychosocial impact.

Early treatment is particularly important when inflammatory nodules, scarring, or significant emotional distress are present.

Selection Of Topical Formulations

The formulation of a topical medication can influence treatment tolerability and adherence.

Creams And Lotions: These preparations are generally less drying than gels or alcohol-based solutions and may be preferable for patients with sensitive or eczema-prone skin.

Gels And Solutions: These formulations may be useful in patients with oily skin or those who prefer lighter preparations.

The most suitable vehicle should be selected according to skin type, treatment location, and patient preference.

Establishing Treatment Expectations

Patients and families should understand that acne treatment usually requires consistent application over several weeks before significant improvement occurs.

Many treatments require approximately 8–12 weeks to demonstrate their full initial benefit.

Some patients experience temporary dryness, irritation, or an apparent increase in acne lesions during the early treatment period.

Medication adherence should be emphasized, and adverse effects should be discussed before starting therapy.

Treatment According To Acne Severity

Mild Acne

Mild acne may consist predominantly of comedones, small inflammatory papules, or a mixture of noninflammatory and inflammatory lesions.

Initial Treatment

Initial therapy may involve a single topical medication or an appropriate combination regimen.

Topical Monotherapy:

• Benzoyl peroxide.
• Topical retinoid.

Topical Combination Therapy:

• Benzoyl peroxide with a topical antibiotic.
• Topical retinoid with benzoyl peroxide.
• Topical retinoid, benzoyl peroxide, and a topical antibiotic.

Topical retinoids are particularly useful for comedonal lesions, while benzoyl peroxide has important antibacterial and anti-inflammatory properties.

Inadequate Treatment Response

When improvement is insufficient, the first step is to assess adherence to the prescribed regimen.

The clinician should determine whether the patient is using medications consistently and whether irritation or other adverse effects are limiting treatment.

If benzoyl peroxide or a topical retinoid has not been included, one may be added when appropriate.

The strength, formulation, or type of topical retinoid may also be adjusted.

An alternative topical combination may be considered when the initial regimen is ineffective or poorly tolerated.

Moderate Acne

Moderate acne typically involves more numerous inflammatory papules and pustules, with or without comedones and limited nodular involvement.

Initial Treatment

Topical combination therapy is generally recommended.

Possible regimens include:

Topical Retinoid And Benzoyl Peroxide: This combination targets abnormal follicular keratinization, bacterial activity, and inflammation.

Topical Retinoid, Benzoyl Peroxide, And Topical Antibiotic: An antibiotic may be added when inflammatory lesions are prominent.

Oral Antibiotic With Topical Retinoid And Benzoyl Peroxide: Systemic antibiotic therapy may be appropriate for more extensive inflammatory acne.

Oral antibiotics should not be used as monotherapy because of the risk of antimicrobial resistance.

Inadequate Treatment Response

If acne remains inadequately controlled, treatment adherence and medication tolerability should be reassessed.

The topical retinoid may be changed in strength, type, or formulation.

The need for an oral antibiotic should be reviewed, and alternative systemic therapy may be considered when appropriate.

In selected postpubertal females, hormonal therapy may be useful.

Patients with persistent inflammatory lesions, early scarring, or significant psychosocial distress may benefit from dermatology referral.

Oral isotretinoin may be considered when appropriate conventional treatments have failed or when the clinical burden is substantial.

Severe Acne

Severe acne is characterized by extensive inflammatory lesions, deep nodules, or marked involvement of the face and trunk.

Scarring and significant psychosocial impairment are common concerns.

Initial Treatment

Oral isotretinoin is an important treatment option for severe, nodular, scarring, or treatment-resistant acne.

An alternative initial approach in selected patients may involve an oral antibiotic combined with a topical retinoid and benzoyl peroxide.

However, prolonged systemic antibiotic treatment should be avoided when isotretinoin is more appropriate.

Early dermatology referral is recommended when severe inflammation, deep nodules, or scarring is present.

Inadequate Treatment Response

Persistent severe acne requires reassessment of adherence, diagnosis, and possible contributing endocrine factors.

If the patient is receiving conventional therapy, treatment may be adjusted by changing the topical retinoid, reconsidering systemic antibiotics, or introducing appropriate hormonal therapy in selected females.

Oral isotretinoin should be strongly considered in suitable patients with persistent severe disease.

Acne Scarring

The presence of active scarring indicates the need for effective control of inflammation.

Aggressive treatment of active inflammatory lesions may prevent additional permanent skin damage.

Patients with substantial scarring should be referred to a dermatologist for comprehensive management.

Medication

Topical And Over-The-Counter Treatments

Several topical products are available for the treatment of mild to moderate acne.

The choice of preparation should consider the predominant lesion type, skin sensitivity, age, and preference of the patient.

Gentle Cleansers

Daily skin cleansing should be performed using a mild, soap-free, pH-balanced cleanser.

The face should generally be washed gently rather than scrubbed vigorously.

Excessive cleansing does not improve acne and may increase irritation, dryness, and disruption of the skin barrier.

Harsh facial astringents, abrasive scrubs, and strongly drying toners should be avoided.

Benzoyl Peroxide

Benzoyl peroxide is a widely used first-line treatment for acne vulgaris.

It has bactericidal, mild comedolytic, and anti-inflammatory effects.

Benzoyl peroxide reduces Cutibacterium acnes activity and is particularly important when combined with topical or oral antibiotics because it helps limit antibiotic resistance.

Available Preparations

Benzoyl peroxide is available in several formulations, including lotions, creams, washes, and gels.

Common concentrations range from 2.5% to 10%.

Treatment Effectiveness

Higher concentrations do not necessarily provide greater effectiveness.

Products containing 2.5–5% benzoyl peroxide are often sufficient for treatment and may cause less irritation than stronger preparations.

Application

Treatment may begin with a lower concentration or reduced application frequency in patients with sensitive skin.

The frequency can be gradually increased as tolerated.

Adverse Effects

Common adverse effects include:

• Skin dryness.
• Erythema.
• Burning or stinging.
• Peeling.
• Irritation.
• Contact dermatitis.

Precautions

Benzoyl peroxide can bleach clothing, towels, bed linen, and hair.

Patients should avoid contact between the medication and fabrics that may become discolored.

Appropriate sun protection and moisturizing products may improve treatment tolerance.

Rare but severe hypersensitivity reactions have been reported with some benzoyl peroxide-containing acne products. Patients should discontinue the product and obtain medical assessment if significant swelling, blistering, or other severe reactions develop.

Salicylic Acid

Salicylic acid is a topical keratolytic agent used in acne treatment.

It promotes shedding of surface skin cells and helps reduce follicular obstruction.

Therapeutic Effects

Salicylic acid may improve mild comedonal acne by promoting exfoliation and reducing accumulation of keratin within follicles.

However, its overall effectiveness is generally less established than that of benzoyl peroxide or topical retinoids.

Adverse Effects

Possible adverse effects include dryness, peeling, erythema, and irritation.

Use over extensive skin areas or with excessive frequency should be avoided, particularly in younger children.

Sulfur And Sulfacetamide

Topical sulfur and sodium sulfacetamide preparations have mild antibacterial and keratolytic properties.

They may be useful in selected patients with mild acne or intolerance to other treatments.

These preparations are generally well tolerated, although dryness or irritation may occur.

A distinctive odor is commonly associated with sulfur-containing products.

Prescription Topical Medications

Topical Antibiotics

Topical antibiotics reduce inflammatory acne by decreasing C. acnes activity and modulating inflammatory processes.

Commonly prescribed agents include clindamycin and erythromycin.

Therapeutic Effects

Topical antibiotics are most effective against inflammatory papules and pustules.

They are less effective as sole treatment for comedonal acne.

Combination Treatment

Topical antibiotics should be combined with benzoyl peroxide to reduce the development of antibiotic-resistant bacteria.

Combination products may improve adherence because fewer separate medications need to be applied.

A topical retinoid may be added to improve comedonal clearance and enhance overall effectiveness.

Adverse Effects

Topical antibiotics are generally well tolerated.

Possible adverse effects include mild dryness, erythema, irritation, and burning.

Antibiotic Resistance

Topical antibiotic monotherapy should be avoided.

Antibiotics should be prescribed for the shortest appropriate duration and combined with nonantibiotic acne treatments.

Topical Retinoids

Topical retinoids are important first-line medications for acne vulgaris.

They act by normalizing follicular keratinization, preventing microcomedone formation, clearing existing comedones, and reducing inflammation.

Topical retinoids are useful in both comedonal and inflammatory acne.

Commonly used agents include adapalene, tretinoin, and tazarotene.

Adapalene

Adapalene is a synthetic topical retinoid used for the treatment of acne.

Available Preparations

It is available as a cream, gel, and combination formulation containing benzoyl peroxide.

Therapeutic Effects

Adapalene helps prevent follicular obstruction and reduces inflammatory acne lesions.

It is relatively photostable and is generally better tolerated than some other topical retinoids.

However, its clinical effectiveness depends on concentration, formulation, and the acne characteristics being treated.

Adverse Effects

Possible adverse effects include dryness, erythema, mild burning, and peeling.

Irritation may be reduced by starting with less frequent application and gradually increasing use as tolerated.

Pregnancy Considerations

Topical retinoids are generally avoided during pregnancy and when pregnancy is being planned because of potential fetal risk, despite relatively low systemic absorption.

Tretinoin

Tretinoin is a topical retinoid that promotes normal follicular epithelial turnover and reduces comedone formation.

Available Preparations

Tretinoin is available in creams, gels, microsphere gels, and other specialized formulations.

Different concentrations are used according to acne severity and skin tolerance.

Application

Tretinoin should be applied to clean, dry skin.

A pea-sized amount is generally sufficient for the entire face.

Applying excessive quantities increases irritation without improving effectiveness.

Initial Treatment

Treatment may begin with a low concentration, such as 0.025%, particularly in patients with sensitive skin.

Application may initially be limited to several nights per week.

The frequency can then be gradually increased as tolerated.

Timing Of Application

Tretinoin is commonly applied at night.

Some conventional tretinoin preparations may undergo degradation when exposed to light or oxidizing agents.

Combination With Benzoyl Peroxide

Traditional tretinoin formulations may be degraded by benzoyl peroxide when applied simultaneously.

For these products, benzoyl peroxide may be used in the morning and tretinoin at night.

However, some newer tretinoin formulations are compatible with simultaneous benzoyl peroxide application, so instructions should be based on the specific product.

Adverse Effects

Common adverse effects include dryness, peeling, redness, burning, and temporary worsening of acne during early treatment.

A noncomedogenic moisturizer may improve tolerance.

Tazarotene

Tazarotene is a topical retinoid used to treat acne vulgaris.

It is generally more irritating than adapalene and may not be the preferred initial retinoid for patients with sensitive skin.

Available Preparations

Tazarotene is available in cream, gel, lotion, and other formulations, depending on the market.

Application

The medication should be applied to clean, dry skin using a thin layer.

A pea-sized amount is generally sufficient for facial application.

Treatment may begin at a low strength and reduced frequency, such as several nights per week.

The frequency may be increased gradually if tolerated.

Therapeutic Adjustment

If acne remains inadequately controlled and the medication is well tolerated, the formulation or concentration may be adjusted.

Adverse Effects

Potential adverse effects include:

• Erythema.
• Dryness.
• Peeling.
• Burning.
• Skin irritation.
• Temporary early acne flare.
• Increased sensitivity to environmental irritants.

Daily noncomedogenic moisturizer and broad-spectrum sunscreen are recommended.

Pregnancy Precautions

Tazarotene is contraindicated during pregnancy because of its teratogenic potential.

Appropriate pregnancy assessment and counseling are necessary for patients who can become pregnant.

Azelaic Acid

Azelaic acid is a topical medication with comedolytic, antimicrobial, and anti-inflammatory properties.

It is also useful in reducing postinflammatory hyperpigmentation.

Available Preparations

Common formulations include 15% gel and 20% cream.

Application

Azelaic acid is often applied once or twice daily according to the prescribed preparation and skin tolerance.

Indications

Azelaic acid may be useful for patients with mild or moderate acne, particularly when postinflammatory pigmentation is a concern.

It may also be considered for patients who cannot tolerate topical retinoids.

Adverse Effects

Possible adverse effects include itching, stinging, burning, erythema, and mild irritation.

Pregnancy Considerations

Azelaic acid is generally regarded as a relatively low-risk topical acne treatment during pregnancy when clinically appropriate.

Topical Dapsone

Topical dapsone is a synthetic sulfone medication with antimicrobial and anti-inflammatory properties.

It is particularly useful for inflammatory acne lesions.

Available Preparations

Dapsone is available in topical gel formulations, including 5% and 7.5% preparations.

Application

The 5% gel is commonly applied twice daily, while some higher-strength formulations are intended for once-daily use.

Application should follow the specific product instructions.

Combination Treatment

Topical dapsone may be combined with a topical retinoid when clinically appropriate.

Adverse Effects

Common adverse effects include dryness, erythema, irritation, and peeling.

Systemic absorption is low, and topical dapsone is generally tolerated in patients with glucose-6-phosphate dehydrogenase deficiency. Nevertheless, clinically significant hemolytic reactions have rarely been reported, and appropriate caution remains necessary.

Interaction With Benzoyl Peroxide

Simultaneous application of topical dapsone and benzoyl peroxide may cause temporary yellow, orange, or brown discoloration of the skin or facial hair.

This discoloration is usually reversible.

Oral Antibiotics

Oral antibiotics are primarily used for moderate to severe inflammatory acne, especially when lesions involve extensive areas of the face, chest, or back.

These medications reduce Cutibacterium acnes activity and suppress inflammatory responses.

Oral antibiotics should not be used as monotherapy. They should generally be combined with benzoyl peroxide and, when appropriate, a topical retinoid.

Systemic antibiotic treatment should be limited to the shortest effective duration, generally approximately three to four months, to reduce antimicrobial resistance.

Tetracycline Antibiotics

Tetracyclines are among the most commonly prescribed systemic antibiotics for inflammatory acne.

Important medications include doxycycline, minocycline, and tetracycline.

These agents have antibacterial and anti-inflammatory properties.

Doxycycline and minocycline are commonly preferred because of their convenient once- or twice-daily administration and penetration into pilosebaceous follicles.

Age Considerations

Tetracycline-class antibiotics are generally avoided for routine prolonged acne treatment in children younger than eight years because of concerns about effects on developing teeth and other age-related prescribing considerations.

Short courses of doxycycline may be appropriate in younger children for specific infections, but this does not establish its suitability for prolonged acne treatment.

Doxycycline

Doxycycline is widely used for moderate to severe inflammatory acne.

A commonly prescribed regimen in appropriate adolescents is 50–100 mg once or twice daily, depending on the formulation and clinical circumstances.

The precise dose should be individualized according to age, weight, disease severity, and product labeling.

Adverse Effects Of Doxycycline

Gastrointestinal Irritation: Nausea, abdominal discomfort, and other gastrointestinal symptoms may occur.

Vaginal Candidiasis: Alteration of normal microbial flora may predispose susceptible patients to candidal infection.

Pill Esophagitis: Doxycycline can irritate the esophagus, particularly when taken without sufficient water or immediately before lying down.

Photosensitivity: Doxycycline may increase susceptibility to sunburn and other phototoxic reactions.

Intracranial Hypertension: Rarely, doxycycline may be associated with increased intracranial pressure, sometimes referred to as pseudotumor cerebri.

Administration Precautions

Doxycycline should be taken with a full glass of water.

Patients should remain upright for at least 30–60 minutes after administration.

Taking the medication with food may improve gastrointestinal tolerance, although product-specific instructions should be followed.

Appropriate sun protection is recommended.

Delayed-release or enteric-coated preparations may improve tolerability in selected patients.

Minocycline

Minocycline is another tetracycline-class antibiotic used for inflammatory acne.

Typical oral dosing depends on the preparation and patient characteristics. Some regimens use approximately 50–100 mg once or twice daily.

Adverse Effects

Vestibular Symptoms: Dizziness, vertigo, and balance disturbances may occur, particularly during early treatment.

Vaginal Candidiasis: Alteration of normal microbial flora may increase susceptibility to candidal infection.

Hyperpigmentation: Prolonged treatment may cause blue-gray or dark pigmentation involving the skin, mucous membranes, or other tissues.

Drug Hypersensitivity: Severe hypersensitivity reactions may develop, sometimes within two to eight weeks after treatment begins.

Lupus-Like Syndrome: Minocycline may rarely induce an autoimmune condition resembling systemic lupus erythematosus.

Autoimmune Hepatitis: Rare cases of immune-mediated liver inflammation have been reported.

Severe Cutaneous Reactions: Stevens-Johnson syndrome and other serious drug reactions may occur rarely.

Intracranial Hypertension: Increased intracranial pressure is an uncommon but important potential complication.

Because minocycline has a different adverse-effect profile from doxycycline, treatment selection should consider individual risk factors.

Tetracycline

Conventional tetracycline is an older oral antibiotic that may be used for acne in selected circumstances.

It is often relatively inexpensive but requires more frequent administration and has limitations related to absorption and tolerability.

Doxycycline and minocycline are generally preferred when systemic tetracycline therapy is appropriate.

Antibiotic Resistance

Increasing antimicrobial resistance is an important concern with prolonged antibiotic treatment.

Tetracycline antibiotics should be combined with benzoyl peroxide and other appropriate topical therapy rather than used alone.

Duration Of Treatment

Clinical response should be reassessed after approximately 8–12 weeks.

Systemic antibiotics should be discontinued when adequate control has been achieved, with continued topical maintenance therapy as appropriate.

Prolonged courses should be avoided unless there is a clear clinical justification.

Trimethoprim-Sulfamethoxazole

Trimethoprim-sulfamethoxazole is not a routine first-line treatment for acne vulgaris.

It may occasionally be considered in selected refractory cases when preferred treatments are unsuitable or ineffective.

Dosage

An example adult-strength regimen used historically is trimethoprim 160 mg with sulfamethoxazole 800 mg orally twice daily.

In pediatric patients, prescribing requires careful consideration of age, weight, indication, and the risk-benefit balance.

Adverse Effects

Potential serious adverse effects include:

• Stevens-Johnson syndrome.
• Toxic epidermal necrolysis.
• Drug hypersensitivity reactions.
• Fixed drug eruptions.
• Bone marrow suppression.

Laboratory Monitoring

A baseline complete blood count and periodic monitoring may be appropriate when prolonged therapy is necessary.

Because of its potential for serious adverse effects, trimethoprim-sulfamethoxazole should be reserved for carefully selected patients.

Cephalosporins

Oral cephalosporins such as cephalexin and cefadroxil have occasionally been used for inflammatory acne when preferred antibiotic classes are unsuitable.

Dosage

A historical regimen for selected older patients is cephalexin 500 mg orally twice daily.

However, dosing in children must be individualized according to weight, age, and clinical circumstances.

Adverse Effects

Cephalosporins are generally well tolerated.

Common adverse effects include nausea, abdominal discomfort, and diarrhea.

Their use for acne is supported by less evidence than tetracycline-class antibiotics, and they are not routinely preferred.

Penicillins

Amoxicillin has occasionally been used as an alternative systemic antibiotic for acne in selected patients.

It is not a standard first-line acne medication because evidence supporting its effectiveness is limited.

Adverse Effects

Common adverse effects include gastrointestinal discomfort, nausea, and diarrhea.

Allergic reactions may also occur.

Macrolides

Macrolide antibiotics such as erythromycin and azithromycin may be considered when tetracyclines are contraindicated or unsuitable.

Erythromycin

Erythromycin has antibacterial and anti-inflammatory properties.

However, resistance of C. acnes to erythromycin is common, limiting its usefulness.

Azithromycin

Azithromycin has occasionally been used for inflammatory acne, although it is not generally a preferred systemic treatment.

Adverse Effects

Macrolides may cause gastrointestinal discomfort, nausea, and diarrhea.

Erythromycin is associated with clinically important drug interactions.

Certain macrolides may also prolong the QT interval in susceptible patients.

Antibiotic Stewardship

Macrolides should be used selectively and for the shortest appropriate duration.

They should not be used as prolonged monotherapy for acne.

Oral Retinoids

Isotretinoin

Oral isotretinoin is a highly effective systemic medication used for severe, nodular, scarring, or treatment-resistant acne.

It acts through several mechanisms, including reduction of sebaceous gland activity, suppression of sebum production, normalization of follicular keratinization, and reduction of inflammation.

Isotretinoin also decreases the follicular environment that supports excessive C. acnes activity.

Indications

Isotretinoin may be indicated in patients with:

• Severe nodular acne.
• Extensive inflammatory acne.
• Acne that has failed appropriate conventional treatment.
• Acne associated with significant or progressive scarring.
• Substantial psychological or social impairment related to acne.

Patients with significant scarring or psychosocial burden may be considered candidates for isotretinoin even when the lesion count alone does not suggest the most severe category.

Treatment Regimen

Isotretinoin is generally prescribed as a systemic treatment without concurrent oral antibiotics.

Topical treatment may be simplified or temporarily discontinued when irritation is prominent.

Initial Dosage

A conventional starting dose is approximately 0.5 mg/kg/day.

The dose may be adjusted according to acne severity, clinical response, and tolerability.

Maintenance Dosage

When tolerated, the daily dose may be increased toward approximately 1 mg/kg/day.

Lower daily doses may be appropriate in patients with substantial adverse effects or increased sensitivity to treatment.

Cumulative Dose

Traditional isotretinoin regimens frequently aim for a cumulative dose of approximately 120–150 mg/kg.

Higher cumulative doses have also been studied.

However, treatment duration and cumulative dosing should be individualized according to clinical response, sustained lesion clearance, and adverse effects rather than relying exclusively on a fixed cumulative target.

Severe Inflammatory Acne

In patients with severe inflammatory or nodulocystic acne, treatment may begin with a lower isotretinoin dose to reduce the risk of an acute inflammatory flare.

In selected severe cases, a short course of systemic corticosteroids may be considered under specialist supervision, particularly when acne fulminans is a concern.

Adverse Effects Of Isotretinoin

Isotretinoin affects several organ systems, and patients require appropriate counseling and clinical monitoring.

Common Mucocutaneous Effects

Dry Skin: Xerosis is extremely common and may require regular use of moisturizers.

Cheilitis: Dry, cracked, or inflamed lips are among the most frequent adverse effects.

Dry Eyes: Reduced tear production may cause eye irritation and discomfort, particularly in contact lens users.

Nasal Dryness: Dryness of the nasal mucosa may contribute to epistaxis.

Skin Sensitivity: Increased irritation and susceptibility to environmental factors may occur.

Musculoskeletal Effects

Muscle aches and joint discomfort may develop during treatment.

Patients who participate in strenuous physical activity may experience increased musculoskeletal symptoms.

Severe or persistent symptoms require clinical reassessment.

Photosensitivity

Some patients experience increased skin sensitivity during treatment.

Daily sun protection and noncomedogenic moisturizers are recommended.

Lipid Abnormalities

Isotretinoin may increase serum triglyceride and cholesterol concentrations.

Severe hypertriglyceridemia may increase the risk of pancreatitis.

Hepatic Effects

Mild elevations in hepatic transaminases may occur.

Clinically significant liver injury is uncommon but requires reassessment of treatment.

Teratogenicity And Pregnancy Prevention

Isotretinoin is a potent teratogen and must not be used during pregnancy.

Exposure during pregnancy may cause severe fetal malformations, pregnancy loss, and other serious developmental complications.

Contraception

Patients who can become pregnant require effective pregnancy prevention according to applicable clinical and regulatory requirements.

Under the United States iPLEDGE program, this generally involves continuous abstinence or two acceptable forms of contraception when contraception is chosen, together with the required pregnancy testing.

Pregnancy prevention must continue throughout treatment and for at least one month after isotretinoin is discontinued.

Pregnancy Testing

Pregnancy testing is required before treatment, during treatment, and after treatment according to the applicable risk-management program.

In the United States, two qualifying negative pregnancy tests are required before treatment initiation, and subsequent pregnancy testing is governed by iPLEDGE requirements.

Regulatory Requirements

In the United States, isotretinoin may only be prescribed and dispensed through the iPLEDGE risk-management system by appropriately registered participants.

Other countries may have different pregnancy prevention and prescribing requirements.

Psychiatric Considerations During Isotretinoin Therapy

Depressive symptoms and suicidal behavior have been reported among patients receiving isotretinoin.

However, population-based studies have not established that isotretinoin causes an overall increase in psychiatric disorders or suicidal behavior.

Acne itself is associated with psychological distress, depression, and impaired quality of life.

Mental Health Assessment

Patients should be assessed for preexisting depression, anxiety, suicidal thoughts, and other psychiatric concerns before and during treatment.

Any significant change in mood or behavior should prompt appropriate clinical evaluation.

Treatment decisions should take account of both the psychological burden of untreated acne and the potential risks associated with medication.

Inflammatory Bowel Disease And Isotretinoin

A possible association between isotretinoin use and inflammatory bowel disease has been investigated.

Available evidence has not established a consistent causal relationship.

Some earlier studies suggested an association, but subsequent research has identified substantial potential confounding factors.

Patients who develop persistent gastrointestinal symptoms, rectal bleeding, or other concerning manifestations should receive appropriate medical evaluation.

Skeletal Effects Of Isotretinoin

The effects of isotretinoin on bone metabolism and skeletal development have been investigated, particularly during prolonged or high-dose treatment.

Reports have described hyperostosis, skeletal discomfort, altered bone mineralization, and premature epiphyseal closure.

These complications are uncommon with conventional acne treatment courses.

The potential skeletal risks should nevertheless be considered when treating younger patients or those requiring unusual treatment durations.

Rare Severe Cutaneous Reactions

Rare severe skin reactions have been reported during isotretinoin treatment.

Examples include erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

New widespread blistering, mucosal erosions, or severe systemic symptoms require immediate medical evaluation.

Important Medication Interaction

Oral isotretinoin should not be used concurrently with tetracycline-class antibiotics.

Combining these medications may increase the risk of drug-induced intracranial hypertension, also known as pseudotumor cerebri.

Symptoms may include severe headache, vomiting, visual disturbance, and papilledema.

Appropriate separation between treatments should be planned when transitioning from a tetracycline antibiotic to isotretinoin.

Hormonal Therapy

Hormonal treatment may be useful for selected postpubertal female patients with moderate to severe acne, particularly when acne is associated with androgen excess or cyclical menstrual flares.

Hormonal medications are often used alongside topical retinoids, benzoyl peroxide, or other acne treatments.

Common options include combined oral contraceptives and spironolactone.

Combined Oral Contraceptives

Combined oral contraceptives can improve acne by suppressing ovarian androgen production and increasing sex hormone-binding globulin, thereby reducing circulating free androgen activity.

Indications

These medications may be considered in postmenarchal adolescents with moderate to severe acne that responds inadequately to appropriate topical treatment.

They may be particularly useful when acne is accompanied by menstrual irregularities or other manifestations of androgen excess.

Approved Preparations

Examples of combined oral contraceptive formulations approved for acne treatment in the United States include:

Ethinyl Estradiol And Norgestimate: Certain preparations containing 35 micrograms of ethinyl estradiol and norgestimate are approved for eligible adolescents aged 15 years or older.

Ethinyl Estradiol And Norethindrone Acetate: Selected preparations containing varying estrogen doses are approved for eligible patients aged 15 years or older.

Ethinyl Estradiol And Drospirenone: Certain preparations containing 20 micrograms of ethinyl estradiol and 3 mg of drospirenone are approved for eligible patients aged 14 years or older.

Age eligibility and specific indications depend on the product label and regulatory jurisdiction.

Pretreatment Assessment

Before prescribing a combined hormonal contraceptive, clinicians should assess:

• Personal tobacco or nicotine use.
• History of venous thromboembolism.
• Family history of thromboembolic disorders.
• Migraine with aura.
• Blood pressure.
• Other contraindications to estrogen-containing medication.

Combined hormonal contraception should be avoided in patients with established contraindications.

Treatment Response

Improvement generally develops gradually.

Patients may require approximately three to six months of treatment before the full effect on acne becomes apparent.

Common Adverse Effects

Potential adverse effects include nausea, breast tenderness, headache, breakthrough menstrual bleeding, and changes in weight or fluid retention.

Serious Adverse Effects

Combined oral contraceptives are associated with a small increased risk of venous thromboembolism.

Rare but serious cardiovascular complications include deep vein thrombosis, pulmonary embolism, ischemic stroke, and myocardial infarction.

Risk assessment is particularly important in patients with additional cardiovascular or thrombotic risk factors.

Bone Health Considerations

The potential effects of hormonal contraceptives on bone mineral accrual during adolescence remain an important consideration.

Treatment should be individualized according to pubertal maturity, reproductive needs, and other medical factors.

There is no universal requirement to delay all combined oral contraceptive use until a fixed interval after menarche.

Spironolactone

Spironolactone is a potassium-sparing diuretic with antiandrogenic properties.

It blocks androgen receptors in sebaceous glands and reduces androgen-mediated stimulation of sebocyte activity.

Indications

Spironolactone may be considered for selected postpubertal female patients with hormonally influenced or persistent inflammatory acne.

It is commonly prescribed off-label for acne.

Dosage

Typical acne regimens may begin with approximately 25 mg daily.

The dose can be increased gradually according to treatment response and tolerability.

Daily doses of approximately 25–150 mg have been used, although treatment should be individualized and prescribed by an appropriate clinician.

Combination Treatment

Spironolactone may be used alongside topical acne treatments or combined oral contraceptives.

Combination therapy may be useful in selected patients with persistent hormonally influenced acne.

Adverse Effects

Potential adverse effects include:

Hyperkalemia: Elevated serum potassium may occur, particularly in patients with renal disease or those receiving medications that increase potassium concentrations.

Hypotension: Blood pressure reduction may lead to dizziness or lightheadedness.

Dizziness: Some patients experience transient dizziness, particularly after treatment initiation or dose increases.

Dry Mouth: Mild dry mouth may occur.

Menstrual Changes: Irregular menstrual bleeding or breast tenderness may occur.

Laboratory Monitoring

Routine potassium monitoring is often unnecessary in otherwise healthy young female patients without renal disease or interacting medications.

Monitoring may be appropriate in patients with underlying kidney disease, relevant comorbidities, or additional risk factors for hyperkalemia.

Pregnancy Precautions

Spironolactone is generally avoided during pregnancy because its antiandrogenic effects may interfere with fetal sexual development.

Patients who can become pregnant should receive appropriate counseling regarding pregnancy prevention.

Complementary And Alternative Therapies

Evidence supporting complementary and alternative treatments for acne remains limited.

Some agents have demonstrated modest effectiveness in small clinical trials, but they generally have less robust evidence than established treatments such as benzoyl peroxide and topical retinoids.

Tea Tree Oil

Tea tree oil contains a mixture of compounds, including terpenes, with antimicrobial and anti-inflammatory properties.

Therapeutic Effects

Topical preparations containing approximately 5% tea tree oil have shown potential benefit in reducing comedonal and inflammatory acne lesions.

However, clinical studies suggest that tea tree oil may be less effective than standard benzoyl peroxide treatment.

Tolerability

Tea tree oil may cause less dryness than some benzoyl peroxide preparations, although allergic contact dermatitis and irritation can occur.

Hormonal Concerns

Laboratory studies and isolated reports have raised questions about possible endocrine effects of certain essential oil products.

However, a causal relationship between topical tea tree oil use and gynecomastia has not been established conclusively.

Tea tree oil products should be used cautiously in children, and undiluted essential oils should not be applied directly to the skin.

Gluconolactone

Gluconolactone is a polyhydroxy acid with exfoliating properties.

Therapeutic Effects

Preparations containing approximately 14% gluconolactone have demonstrated potential benefit for both comedonal and inflammatory acne in limited clinical studies.

Tolerability

Gluconolactone may produce less irritation than some stronger topical acne treatments.

However, evidence supporting its effectiveness remains limited, and it is not generally considered a preferred first-line treatment.

Ongoing Care

Follow-Up Recommendations

Follow-up should focus on disease severity, treatment effectiveness, medication adherence, adverse effects, and psychosocial well-being.

Patients receiving topical therapy should generally be reassessed after sufficient time has elapsed to evaluate treatment response, commonly around 8–12 weeks.

Earlier review may be necessary when substantial irritation, severe inflammatory acne, or significant psychological distress is present.

Assessment Of Treatment Response

The clinician should evaluate changes in:

• Number of comedonal lesions.
• Number and severity of inflammatory lesions.
• Development of new nodules.
• Formation of scars.
• Postinflammatory pigmentary changes.
• Treatment tolerability.
• Patient satisfaction and quality of life.

Medication Adherence

Poor adherence is a frequent reason for inadequate acne control.

Patients should be asked about difficulties related to cost, irritation, application frequency, inconvenience, and treatment expectations.

Simplifying the regimen or changing formulations may improve adherence.

Maintenance Therapy

Acne often requires ongoing maintenance treatment after the initial inflammatory lesions improve.

Topical retinoids, benzoyl peroxide, or other appropriate nonantibiotic medications may be continued to reduce recurrence.

Long-term antibiotic monotherapy should be avoided.

Patient Education

Understanding Acne

Patients and families should understand that acne is a common inflammatory disorder involving sebaceous glands and hair follicles.

It is not caused simply by poor hygiene or dirty skin.

Excessive washing and abrasive skin care do not eliminate acne and may aggravate irritation.

Daily Skin Care

A gentle cleanser should be used regularly.

Noncomedogenic moisturizers can help reduce medication-related dryness and maintain skin barrier function.

Patients should avoid harsh exfoliation, abrasive scrubbing, and repeated manipulation of active lesions.

Sunscreen Use

Broad-spectrum sunscreen with SPF 30 or higher should be used regularly.

Noncomedogenic formulations are preferred to reduce the likelihood of follicular occlusion.

Sun protection may also help prevent worsening of postinflammatory hyperpigmentation.

Cosmetic Products

Oil-free, noncomedogenic cosmetics and skin care products are generally preferred.

Heavy oil-based products should be avoided when they consistently worsen acne.

Treatment Expectations

Patients should be informed that meaningful improvement may require several weeks.

Consistent treatment is usually more effective than frequently changing medications or applying excessive quantities.

Temporary dryness, peeling, or irritation may occur during the early stages of treatment.

Prevention Of Scarring

Patients should avoid squeezing or picking at inflammatory lesions.

Early treatment of nodular and persistent inflammatory acne is important because established scars may be permanent.

Emotional And Social Support

The psychological effects of acne should be acknowledged and addressed.

Adolescents experiencing embarrassment, social withdrawal, depression, or reduced quality of life may benefit from additional support.

Mental health assessment should be offered when depressive symptoms or suicidal thoughts are identified.

Complications

Permanent Scarring

Acne may cause permanent scarring, particularly when inflammation extends into deeper dermal tissues.

Atrophic scars are common and may appear as depressed areas of skin.

Hypertrophic scars and keloids may also develop, especially on the chest, shoulders, and back.

The risk of scarring increases with severe inflammatory disease, prolonged untreated acne, and manipulation of lesions.

Early effective treatment is essential to reduce permanent skin damage.

Postinflammatory Hyperpigmentation

Postinflammatory hyperpigmentation develops when inflammation stimulates increased melanin production.

It is particularly common and may be more persistent in individuals with darker skin phototypes.

Pigmented areas may gradually fade after active acne is controlled, but resolution can require months or years.

Topical retinoids, azelaic acid, and appropriate sun protection may help improve pigmentation.

Postinflammatory Erythema

Some patients develop persistent red or pink marks following resolution of inflammatory lesions.

These changes result primarily from residual vascular alterations rather than excess pigmentation.

They may improve gradually over time.

Reduced Self-Esteem

Acne can negatively affect body image and self-confidence, particularly during adolescence.

Affected teenagers may experience embarrassment, self-consciousness, and reduced participation in social activities.

Psychosocial impairment does not always correlate directly with the number or severity of lesions.

Even clinically mild acne may cause substantial emotional distress.

Depression And Suicidal Ideation

Depressive symptoms have been observed in adolescents with acne, including those with mild or moderate disease.

Some clinical studies have reported suicidal ideation in more than 5% of affected patients, although prevalence estimates vary across study populations.

Improvement in acne severity may be associated with reduced depressive symptoms and better quality of life.

Clinicians should therefore assess psychological well-being as part of routine acne management.

Social And Functional Impairment

Acne may interfere with school participation, interpersonal relationships, recreational activities, and overall emotional development.

Patients may avoid social situations because of embarrassment or fear of negative evaluation.

Effective dermatological treatment, education, and appropriate psychological support can help reduce these complications.